Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021

Rhea-AI Summary

Oyster Point Pharma (Nasdaq: OYST) announced its participation at the American Academy of Optometry Annual Meeting 2021, occurring from November 3-6 in Boston, MA. The company will present multiple data from clinical trials focused on its recently FDA-approved product, TYRVAYA™ (varenicline solution) Nasal Spray, designed to treat dry eye disease. Presentations will cover efficacy, treatment outcomes, and safety assessments related to TYRVAYA. Dry eye disease affects approximately 38 million individuals in the U.S., highlighting the importance of innovative treatments in this growing market.

PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced multiple scientific presentations at the American Academy of Optometry (AAOpt) Annual Meeting 2021 being held in Boston, MA November 3 - 6, 2021.

“The American Academy of Optometry annual meeting is the largest meeting in optometry and works to provide exceptional education, support innovative research, and disseminate knowledge to advance optometric practice and improve patient care,” said Marian Macsai, MD Chief Medical Officer of Oyster Point Pharma. “We are pleased to share a number of data presentations from company-sponsored clinical trials at this year’s meeting highlighting the recently approved TYRVAYAÔ (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease.”

Papers/Posters

Title: Effect of OC-01 (varenicline solution) Nasal Spray Compared to Vehicle Control on Dry Eye Disease Sign Outcomes by Baseline Subgroup Characteristics
Presenter: Leslie O’Dell, OD
Date/Time: Thursday, November 4th, 4:30 – 6:30pm ET

Title: OC-01 (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease in Subjects with Mild, Moderate, and Severe Dry Eye Disease as Determined by Baseline Eye Dryness Score: ONSET-1 and ONSET-2 Trial Outcomes
Presenter: Paul Karpecki, OD
Date/Time: Thursday, November 4th, 4:30 – 6:30pm ET

Title: Safety Assessment of OC-01 (varenicline) Nasal Spray in Subjects with Dry Eye Disease
Presenter: Walter O. Whitley, OD
Date/Time: Thursday, November 4th, 4:30 – 6:30pm ET

About Dry Eye Disease and the Role of Tear Film
Dry eye disease is a chronic condition that impacts an estimated 38 million people in the U.S. and is growing in prevalence^1,2. It can cause persistent stinging, scratching, burning sensations, sensitivity to light, blurred vision, and eye fatigue. Dry eye disease is a multifactorial disease of the ocular surface characterized by disruption of the tear film. Human tear film is a complex mixture of more than 1,500 different proteins, including growth factors and antibodies, as well as numerous classes of lipids and mucins³. Natural tear film protects and lubricates the eyes, washes away foreign particles, contains growth factors and antimicrobial components, and creates a smooth surface that forms the primary refractive surface of the eye.

About TYRVAYA™ (varenicline solution) Nasal Spray
TYRVAYA (varenicline solution) Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray. The parasympathetic nervous system, the “rest and digest” system of the body, controls tear film homeostasis partially via the trigeminal nerve, which is accessible within the nose. The efficacy of TYRVAYA Nasal Spray in dry eye disease is believed to be the result of varenicline's activity at heteromeric sub-type(s) of the nicotinic acetylcholine (nACh) receptor where its binding produces agonist activity and activates the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease. Varenicline binds with high affinity and selectivity at human α4β2, α4α6β2, α3β4, α3α5β4 and α7 neuronal nicotinic acetylcholine receptors. The exact mechanism of action is unknown at this time.

TYRVAYA™ Important Safety Information
The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation. There are no contraindications associated with TYRVAYAÔ (varenicline solution) Nasal Spray.

Please see full Prescribing Information at www.tyrvaya-pro.com/prescribinginformation.

About Oyster Point Pharma, Inc.
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA-approval for TYRVAYAÔ (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations. Oyster Point is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them. For more information, visit www.oysterpointrx.com and follow @OysterPointRx on Twitter and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma (the “Company” or “our”) regarding the future of the Company’s business, our future plans and strategies, regulatory approvals, preclinical and clinical results, future financial condition and other future conditions. All statements other than statements of historical facts contained in this press release, including express or implied statements regarding plans and objectives of management for future operations, future results of operations and financial position, business strategy, product candidates, regulatory approvals, planned future product commercialization, planned preclinical studies and clinical trials, expected results of preclinical studies or clinical trials, and their timing and likelihood of success, expected research and development commercialization costs, are forward-looking statements. The words “if approved,” “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our plans and potential for success relating to commercializing TYRVAYA; the beneficial characteristics, safety, efficacy and therapeutic effects of TYRVAYA and our preclinical and clinical product candidates; our plans relating to the further development and manufacturing of TYRVAYA and our preclinical and clinical candidates, including potential additional indications or disease areas to be evaluated and pursued; the timing of initiation of our future preclinical studies or clinical trials; the uncertainties inherent in pharmaceutical research and development, including preclinical study and clinical trial results and additional analysis of existing data; the likelihood of clinical trials demonstrating safety and efficacy of our product candidates, and other positive results; the timing or likelihood of regulatory filings and approvals TYRVAYA and our clinical and preclinical candidates, including in potential additional indications for TYRVAYA and potential filings in additional jurisdictions; our plans and ability to obtain or protect intellectual property rights including extensions of existing patent terms where available; our ability to recruit and retain key personnel needed to develop and commercialize our product candidates, if approved, and to grow our company; existing regulations and regulatory developments in the United States and other jurisdictions; our continued reliance on third parties to conduct additional preclinical studies and clinical trials of our product candidates, and for the manufacture of our product candidates for potential commercialization and for preclinical studies and clinical trials; the impact of the COVID-19 pandemic on our business, operations, and regulatory and clinical development timelines; the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our financial performance; market conditions; the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements; and other risks described in the “Risk Factors” section included in our public filings that we have made and will make with the Securities and Exchange Commission (SEC). The Company is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Investor Contact
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com

Media Contact
Sheryl Seapy
Real Chemistry
(213) 262-9390
sseapy@realchemistry.com

Sources:

1.   Market-Scope. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. October 2020.
2.   Tsubota K, Pflugfelder S, Liu Z, Baudouin C. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020;21(23):1-24.
https://pubmed.ncbi.nlm.nih.gov/33291796/
3.   Willcox, M. D., Argüeso, P., Georgiev, G. A., Holopainen, J. M., Laurie, G. W., Millar, T. J., ... & Jones, L. (2017). TFOS DEWS II tear film report. The ocular surface, 15(3), 366-403.

FAQ

What presentations will Oyster Point Pharma showcase at the AAOpt Annual Meeting 2021?

Oyster Point Pharma will present data on TYRVAYA™ (varenicline solution) Nasal Spray, including treatment outcomes and safety assessments, on November 4, 2021.

When is the AAOpt Annual Meeting 2021 where Oyster Point Pharma is presenting?

The AAOpt Annual Meeting 2021 is scheduled from November 3-6, 2021, in Boston, MA.

What is TYRVAYA™ and its significance?

TYRVAYA™ is an FDA-approved nasal spray for the treatment of dry eye disease, a condition affecting 38 million people in the U.S. It improves tear production via the trigeminal nerve.

How prevalent is dry eye disease in the U.S.?

Dry eye disease impacts an estimated 38 million people in the U.S., highlighting the need for effective treatments like TYRVAYA™.

What are the common adverse reactions associated with TYRVAYA™?

The most reported adverse reaction to TYRVAYA™ is sneezing, experienced by 82% of patients, with other reactions including cough and throat irritation.